Support for QA/QC for Prior Approval Process

整体杜克CTSA赠款摘要： 杜克临床和转化科学研究所的使命是促进 通过合作研究将科学发现转化为人口健康效益。既往临床 和转化科学奖（CTSA）的资金，我们已经成功地开发了基础设施， 提供资源，以支持临床和转化科学和劳动力的研究者 光谱我们的成就促进了高影响力的发现，提高了研究效率， 培养了更有能力和更多样化的劳动力。我们还开启了一个合作科学的新时代 在杜克大学。已经启动了几个新的跨学科项目，将学员和教师联系起来 从我们的医学院，护理，工程，商业，艺术和科学，以提高 翻译.在下一阶段，杜克建议利用三大新机遇， 举措首先，我们将优化临床和转化科学国家网络的方法， 流程.基于杜克在协调多中心临床试验方面的领先经验， 国家杜克-范德比尔特NCATS试验创新中心，我们将开发优化“本地枢纽”的方法， NCATS试验创新网络的“中心到网络”和“网络到网络”流程。我们将 还帮助研究人员利用一些额外的NIH网络资源，并提供方法， 在CTSA网络中传播最佳做法。二是深化、培育、延伸 利益相关者的合作。我们将加强现有的伙伴关系，并与 机构和研究者层面的利益攸关方。伙伴关系和方案将扩大 CTSI活动的广度和透明度。我们还将支持调查人员更多地参与， 广泛的患者、社区团体、临床医生、医疗保健系统、行业、企业 资本家、付款人、决策者和其他人。第三，我们将进一步促进杜克大学的科学整合。 一支训练有素的专业队伍将促进重大的跨学科科学举措。一个新 大学范围内的协调基础设施将进一步扩大合作，弥合科学孤岛。我们 还将通过提高团队科学技能、研究团队流程以及 促进对我们机构团队贡献的认可。总的来说，这些活动将扩大 我们的研究在国家，地区和地方的创新和影响。我们将衡量结果 这反映了在翻译发现、使用国家最佳做法、机构和 调查员团队合作、研究透明度和社区信任。我们将分享所有最佳实践， CTSA网络。我们相信，我们的成就将有意义地提高临床和 美国的健康转化科学。

Abstract of overall Duke CTSA grant: The mission of the Duke Clinical and Translational Science Institute is to catalyze the translation of scientific discoveries into population health benefits through collaborative research. With previous Clinical and Translational Science Award (CTSA) funding, we have successfully developed infrastructure and provided resources to support investigators across the clinical and translational scientific and workforce spectrums. Our achievements have facilitated high-impact discoveries, increased research efficiency, and nurtured a more capable and diverse workforce. We have also ignited a new era of collaborative science at Duke. Several new transdisciplinary programs have been launched, connecting trainees and faculty from our Schools of Medicine, Nursing, Engineering, Business, and Arts and Sciences to enhance translation. In the next phase, Duke proposes to capitalize on new opportunities with three broad initiatives. First, we will optimize clinical and translational science national networks’ methods and processes. Building on Duke’s leading experience coordinating multi-center clinical trials including its national Duke-Vanderbilt NCATS Trial Innovation Center, we will develop methods to optimize ‘local hub,’ ‘hub-to-network’, and ‘network-to-network’ processes for the NCATS Trial Innovation Network. We will also help investigators leverage a number of additional NIH network resources and provide methods to disseminate best practices throughout the CTSA network. Second, we will deepen, nurture, and extend stakeholder collaborations. We will strengthen existing partnerships and foster new ones with stakeholders at both the institutional and investigator levels. Partnerships and programs will expand the breadth and transparency of CTSI activities. We will also support investigators’ greater engagement with a broad range of patients, community groups, clinicians, health care systems, industry, venture capitalists, payers, policy makers, and others. Third, we will catalyze further science integration at Duke. An invigorated professional workforce will facilitate major transdisciplinary science initiatives. A new University-wide coordination infrastructure will further amplify collaboration and bridge science siloes. We will also support teams by improving their skills in team science, studying team processes, and by promoting the recognition of team contributions at our institution. Collectively, these activities will amplify the innovation and impact of our research nationally, regionally, and locally. We will measure outcomes that reflect improvement in the translation of discoveries, use of national best practices, institutional and investigator teamwork, research transparency, and community trust. We will share all best practices with the CTSA network. We believe our achievements will meaningfully enhance the impact of clinical and translational science on health across the United States.